Storia in 2 fonti

Ying Huang's post-Legend life takes shape at K2, with $250M goal to license Asia assets

Ying Huang, ex-Legend Biotech CEO, joins K2 Therapeutics as CEO. Firm targets 20 assets, raised $50M from MPM BioImpact, seeks $250M Series A.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo3 g fa

Ying Huang's post-Legend life takes shape at K2, with $250M goal to license Asia assets

Ying Huang, ex-Legend Biotech CEO, joins K2 Therapeutics as CEO. Firm targets 20 assets, raised $50M from MPM BioImpact, seeks $250M Series A.

originale

biopharmadive.com4 g fa

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

Leggi questa versione → originale

Timeline cronologica

martedì 11 agosto 2026·biopharmadive.com
Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs
Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.
martedì 11 agosto 2026·endpoints.news
Ying Huang's post-Legend life takes shape at K2, with $250M goal to license Asia assets
Ying Huang, ex-Legend Biotech CEO, joins K2 Therapeutics as CEO. Firm targets 20 assets, raised $50M from MPM BioImpact, seeks $250M Series A.